



**Supplementary Fig. S3.** Effects of neutralizing antibodies on plasma ozoralizumab concentration and ACR20 response.

<sup>a</sup>Trough concentrations of the neutralizing antibody–positive patients in the 30 mg group were not calculated because a large number of the measurements were below the limit of quantification.

<sup>b</sup>Trough concentrations of the neutralizing antibody–positive patients in the 80 mg group are not shown as only one patient in the 80 mg group was neutralizing antibody–positive by week 8.

ACR20  $\geq$  20% improvement according to the American College of Rheumatology criteria, SD standard deviation.

**OHZORA trial**



**NATSUZORA trial**

